Sangamo Announces Capsid License Agreement with Lilly to Delivery Genomic Medicines for Diseases of the Central Nervous System

Click here to view

Presentation

Poster: Development of Blood-Brain Barrier Penetrant AAVs through Receptor-Targeted Capsid Engineering

Download PDF